Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.1925
| Title: | The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors | Authors: | Ko T.K. Chuah C.T. Huang J.W. Ng K.-P. Ong S.T. |
Keywords: | BCR ABL protein BH3 protein imatinib navitoclax protein bcl 2 protein bcl xl protein tyrosine kinase inhibitor venetoclax 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide aniline derivative antineoplastic agent benzamide derivative fused heterocyclic rings imatinib navitoclax piperazine derivative protein bcl 2 protein kinase inhibitor pyrimidine derivative sulfonamide Article blood toxicity cell death chronic myeloid leukemia drug activity human human cell IC50 maximum tolerated dose protein expression thrombocyte lifespan thrombocytopenia antagonists and inhibitors apoptosis cancer stem cell drug effects drug resistance drug screening Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism tumor cell line Aniline Compounds Antineoplastic Agents Apoptosis Benzamides Bicyclo Compounds, Heterocyclic Cell Line, Tumor Drug Resistance, Neoplasm Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplastic Stem Cells Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-bcl-2 Pyrimidines Sulfonamides Tumor Stem Cell Assay |
Issue Date: | 2014 | Citation: | Ko T.K., Chuah C.T., Huang J.W., Ng K.-P., Ong S.T. (2014). The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 5 (19) : 9033-9038. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.1925 | Abstract: | BCR-ABL1-specific tyrosine kinase inhibitors prolong the life of patients with chronic myeloid leukemia (CML) but cannot completely eradicate CML progenitors. The BH3 mimetic, ABT-263, targets prosurvival BCL2 family members, and has activity against CML progenitors. However, the inhibitory effect of ABT-263 on BCL-XL, which mediates platelet survival, produces dose-limiting thrombocytopenia. A second-generation BH3 mimetic, ABT-199, has been developed to specifically bind BCL2 but not BCL-XL. We determined the activity of ABT-199 against CML cell lines, as well as primary CML and normal cord blood (NCB) progenitors. We find that BCL2 expression levels predict sensitivity to ABT-199 in CML and NCB progenitors, and that high NCB BCL2 levels may explain the reported hematologic toxicities in ABT-199-treated patients. Also, while single agent ABT-199 has modest activity against CML progenitors, when combined with imatinib, ABT-199 significantly enhances imatinib activity against CML progenitors at concentrations predicted to avoid hematologic toxicities. | Source Title: | Oncotarget | URI: | https://scholarbank.nus.edu.sg/handle/10635/174163 | ISSN: | 19492553 | DOI: | 10.18632/oncotarget.1925 |
| Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| 10_18632_oncotarget_1925.pdf | 1.13 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.